Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8499 USD | -2.31% | -6.09% | -19.06% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Capitalization 1 | 1,507 | 819.5 | 377.1 | 23.03 | 45.01 |
Enterprise Value (EV) 1 | 1,408 | 686.1 | 271.4 | -66.7 | -16.23 |
P/E ratio | -28.9 x | -10.5 x | -4.17 x | -0.41 x | -1.25 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -36.1 x | -8.73 x | -3.02 x | 1.34 x | 0.67 x |
EV / FCF | -69.8 x | -28 x | -8.89 x | 2.76 x | 8.36 x |
FCF Yield | -1.43% | -3.58% | -11.3% | 36.3% | 12% |
Price to Book | 13.1 x | 4.76 x | 3.2 x | 0.23 x | 0.53 x |
Nbr of stocks (in thousands) | 26,852 | 29,498 | 29,878 | 36,130 | 42,869 |
Reference price 2 | 56.14 | 27.78 | 12.62 | 0.6374 | 1.050 |
Announcement Date | 3/16/20 | 3/1/21 | 3/1/22 | 3/15/23 | 4/1/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -12.07 | -38.98 | -78.56 | -89.97 | -49.89 | -24.32 |
EBIT 1 | -12.12 | -39.17 | -78.89 | -90.32 | -50.09 | -24.64 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -12.48 | -36.98 | -76.85 | -89.94 | -51.94 | -31.58 |
Net income 1 | -12.48 | -36.98 | -76.85 | -89.94 | -51.66 | -31.38 |
Net margin | - | - | - | - | - | - |
EPS 2 | -3.711 | -1.943 | -2.634 | -3.027 | -1.542 | -0.8428 |
Free Cash Flow 1 | -8.464 | -20.18 | -24.54 | -30.54 | -24.18 | -1.941 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/4/19 | 3/16/20 | 3/1/21 | 3/1/22 | 3/15/23 | 4/1/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 |
---|---|---|---|
Net sales 1 | - | - | - |
EBITDA 1 | -23.46 | -21.82 | -16.17 |
EBIT 1 | -23.54 | -21.86 | -16.26 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -23.4 | -21.64 | -16.85 |
Net income 1 | -23.4 | -21.64 | -16.56 |
Net margin | - | - | - |
EPS 2 | -0.7800 | -0.7200 | -0.5100 |
Dividend per Share | - | - | - |
Announcement Date | 3/1/22 | 5/10/22 | 8/9/22 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 71.7 | 99.9 | 133 | 106 | 89.7 | 61.2 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -8.46 | -20.2 | -24.5 | -30.5 | -24.2 | -1.94 |
ROE (net income / shareholders' equity) | -36.5% | -39.6% | -53.4% | -61.9% | -47.1% | -33.8% |
ROA (Net income/ Total Assets) | -18.8% | -24.8% | -31.4% | -35% | -26.4% | -11.3% |
Assets 1 | 66.38 | 149 | 244.6 | 257.1 | 195.7 | 277 |
Book Value Per Share 2 | -9.560 | 4.300 | 5.830 | 3.940 | 2.780 | 1.980 |
Cash Flow per Share 2 | 7.290 | 1.910 | 2.260 | 2.320 | 1.230 | 0.4800 |
Capex 1 | 0.21 | 0.06 | 0.05 | 0.18 | 0.13 | 0.16 |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/4/19 | 3/16/20 | 3/1/21 | 3/1/22 | 3/15/23 | 4/1/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.06% | 37.6M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- QNCX Stock
- Financials Quince Therapeutics, Inc.